TFF Pharmaceuticals (TFF Pharmaceuticals) Net Income (Continuing Operations) : $-21.24 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is TFF Pharmaceuticals Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. TFF Pharmaceuticals's Net Income (Continuing Operations) for the three months ended in Dec. 2023 was $-4.76 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 was $-21.24 Mil.

TFF Pharmaceuticals Net Income (Continuing Operations) Historical Data

The historical data trend for TFF Pharmaceuticals's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TFF Pharmaceuticals Net Income (Continuing Operations) Chart

TFF Pharmaceuticals Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income (Continuing Operations)

Get a 7-Day Free Trial

-11.87

-18.57

-31.04

-31.77

-21.24

TFF Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Income (Continuing Operations)	Get a 7-Day Free Trial															-7.37	-7.05	-5.02	-4.41	-4.76

TFF Pharmaceuticals Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.24 Mil.

TFF Pharmaceuticals (NAS:TFFP) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

TFF Pharmaceuticals Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of TFF Pharmaceuticals's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

TFF Pharmaceuticals (TFF Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TFF Pharmaceuticals Inc (NAS:TFFP) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

N/A

Address

1751 River Run, Suite 400, Fort Worth, TX, USA, 76107

Website

https://www.tffpharma.com

TFF Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It is focused on the development of inhaled dry powder drugs for the treatment of lung disorders.

Executives

Carlson Capital L P	10 percent owner	2100 MCKINNEY AVE, STE 1900, DALLAS TX 75201
Clint Duane Carlson	10 percent owner	2100 MCKINNEY AVENUE, SUITE 1800, DALLAS TX 75201
Zamaneh Mikhak	officer: Chief Medical Officer	1751 RIVER RUN, SUITE 400, C/O TFF PHARMACEUTICALS, INC., FORT WORTH TX 76107
Robert S Mills	director	8 MISTY BROOK LANE, NEW FAIRFIELD CT 06812
Kirk Allen Coleman	officer: CFO, Secretary, and Treasurer	2600 VIA FORTUNA, SUITE 360, AUSTIN TX 78746
Stephen Rocamboli	director	C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Asgard Investment Corp. Ii	10 percent owner	2100 MCKINNEY AVENUE, SUITE 1800, DALLAS TX 75201
Double Black Diamond Offshore Ltd	10 percent owner	CITCO FUND SERVICES, 89 NEXUS WAY, P.O. BOX 31106, CAMANA BAY E9 KY-1205
Harlan F Weisman	director	C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Brandi Roberts	director	12390 EL CAMINO REAL #150, SAN DIEGO CA 92130
Fletcher Aaron G.l.	director	40 GUEST STREET, BOSTON MA 02135
Randy H Thurman	director	222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654
Glenn R. Mattes	director, officer: President and CEO	200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Malcolm Fairbairn	director	C/O ASCEND CAPITAL, LLC, 4 ORINDA WAY, SUITE 200-C, ORINDA CA 94563
Lung Therapeutics, Inc.	10 percent owner	P.O. BOX 150183, AUSTIN TX 78715